BioXcel Therapeutics, Inc. BTAI 深 滬
已收盤 03-27 16:00:00 美东时间
1.26
-0.110
-8.03%
華盛通- 最 高1.42
- 今 開1.42
- 成交量 96.33万股
- 最 低 1.25
- 昨 收 1.37
- 總市值 3086.56万
- 52周最高 8.08
- 市盈率 靜 --
- 換手率 3.93%
- 52周最低 1.17
- 委 比 94.53%
- 總股本 2449.65万
- 歷史最高 1144.00
- 量 比 1.73
- 振 幅 12.41%
- 歷史最低 1.25
- 每 手 1
- 風險率 0.94%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Earnings Scheduled For March 27, 2026
Companies Reporting Before The Bell • Instil Bio (NASDAQ:TIL) is expected to re...
03-27 19:11
BioXcel Therapeutics Q4 EPS $(0.58) Beats $(0.69) Estimate, Sales $256.000K Beat $250.000K Estimate
BioXcel Therapeutics (NASDAQ:BTAI) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.69) by 16.31 percent. This is a 83.75 percent increase over losses of $(3.57) per share
03-27 19:04
美股大行评级 | 摩根大通上调哔哩哔哩至"超配"，目标价从27美元升至35美元；Rhythm遭花旗、大摩等多家机构下调目标价
今日重点评级关注：韦德布什：维持Black Diamond Therapeutic"跑赢大市"评级，目标价从13美元升至14美元；花旗：维持Olema Pharmaceuticals"买入"评级，目标价从60美元升至62美元
03-18 10:48
Rodman & Renshaw Initiates Coverage On BioXcel Therapeutics with Buy Rating, Announces Price Target of $17
Rodman & Renshaw analyst Michael King initiates coverage on BioXcel Therapeutics (NASDAQ:BTAI) with a Buy rating and announces Price Target of $17.
03-17 20:06
BioXcel Therapeutics Announces Registered Direct Equity Financing
Bioxcel Therapeutics ( ($BTAI) ) just unveiled an update. On March 10, 2026, Bi...
03-12 09:09
BioXcel Therapeutics Commences ~$8M Offering Of Common Stocks, Warants
BioXcel Therapeutics, Inc. (the "Company") (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence to develop transformative medicines in neuroscience, today announced that it has entered into a
03-11 02:37
Why Are BioXcel Therapeutics Shares Down Friday?
BioXcel Therapeutics shares fall after a rally as BXCL501 Phase 2 data show promise for treating opioid withdrawal symptoms.
03-06 23:27
美股大行评级 | 最高582美元！博通获多家机构上调目标价；GENI、Okta、Rigetti Computing、Veeva Systems、Wix.com遭多家机构下调目标价
今日重点评级关注：韦德布什：维持TScan Therapeutics"跑赢大市"评级，目标价从4美元升至5美元；HC Wainwright & Co.：维持莱斯康制药"买入"评级，目标价从4美元升至6美元
03-06 11:58
HC Wainwright & Co. Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $6
HC Wainwright & Co. analyst Raghuram Selvaraju maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and lowers the price target from $10 to $6.
03-06 00:36
BioXcel Therapeutics Stock Rallies Opioid Study Success
BioXcel Therapeutics' stock rises premarket after Phase 2 data show BXCL501 reduced opioid withdrawal symptoms and may rival Lucemyra.
03-05 21:53
